

**Research Paper** 



2017; 7(17): 4087-4098. doi: 10.7150/thno.20548

# Enhanced Radiotherapy using Bismuth Sulfide Nanoagents Combined with Photo-thermal Treatment

Xiaju Cheng<sup>1\*</sup>, Yuan Yong<sup>3, 4\*</sup>, Yiheng Dai<sup>2</sup>, Xin Song<sup>1</sup>, Gang Yang<sup>1</sup>, Yue Pan<sup>2<sup>III</sup></sup>, Cuicui Ge<sup>1<sup>III</sup></sup>

- 1. School of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China;
- State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China;
- 3. College of Chemistry and Environment Protection Engineering, Southwest Minzu University, Chengdu 610041, China;
- 4. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.

\* Equal contribution

🖂 Corresponding authors: ccge@suda.edu.cn, panyue@suda.edu.cn

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2017.04.13; Accepted: 2017.08.02; Published: 2017.09.20

#### Abstract

Nanotechniques that can improve the effectiveness of radiotherapy (RT) by integrating it with multimodal imaging are highly desirable.

**Results** In this study, we fabricated  $Bi_2S_3$  nanorods that have attractive features such as their ability to function as contrast agents for X-ray computed tomography (CT) and photoacoustic (PA) imaging as well as good biocompatibility. Both *in vitro* and *in vivo* studies confirmed that the  $Bi_2S_3$ nanoagents could potentiate the lethal effects of radiation *via* amplifying the local radiation dose and enhancing the anti-tumor efficacy of RT by augmenting the photo-thermal effect. Furthermore, the nanoagent-mediated hyperthermia could effectively increase the oxygen concentration in hypoxic regions thereby *inhibiting* the *expression* of hypoxia-inducible factor (*HIF-1a*). This, in turn, interfered with DNA repair *via* decreasing the expression of DNA repair-related proteins to overcome radio-resistance. Also, RT combined with nanoagent-mediated hyperthermia could substantially suppress tumor metastasis *via* down-regulating angiogenic factors.

**Conclusion** In summary, we constructed a single-component powerful nanoagent for CT/PA imaging-guided tumor radiotherapy and, most importantly, explored the potential mechanisms of nanoagent-mediated photo-thermal treatment for enhancing the efficacy of RT in a synergistic manner.

Key words: multimodal imaging; radiation therapy; hypoxia; DNA repair; synergistic therapy.

## Introduction

Radiotherapy (RT), alone or in combination with other treatments, is commonly used in cancer treatment with up to 50% of cancer patients receiving this treatment modality [1, 2]. Ionizing irradiation, by reacting with the aqueous environment, induces bursts of reactive oxygen species (ROS) that are also capable of reacting with important biomolecules such as DNA, proteins, and the fatty-acid moieties of phospholipid cell membranes [3-6]. Nevertheless, external RT in which high-energy radiation (X-ray or  $\gamma$ -ray) is used suffers from a series of limitations, including serious injuries to normal tissues [7-9]. Furthermore, due to the hypoxic internal tumor microenvironment, tumor cells are less sensitive to ionizing radiation compared with normal cells [10], which is the reason for the resistance or failure of RT. Previous studies have shown that mild hyperthermia treatment can improve the inadequacy of oxygen supply in tumor vascular systems [11-13]. In this respect, some nanomaterials hold great promise due to their sensitivity to internal/external redox stimuli [14-16].

A greater local radiation dose can be concentrated by radiosensitizers with strong photoelectric absorbance capacities [17-22]. For this purpose, nanomaterials with high atomic number (Z), such as Au, rare earth elements, W, Pt and Bi, have been introduced. Thus, an improvement in the efficacy of RT for cancer cells is achieved while minimizing the radio-toxicity to the surrounding normal tissues [23-25]. Among numerous intensifiers, bismuth-based nanomaterials are predicted to be superior to others not only because of their ability to enhance the radiation dose but also because of their use in multimodal imaging [26-30]. Bismuth-based nanomaterials such as Bi2S3 nanodots and Bi2Se3 nanoplates have been employed as CT contrast agents due to their high X-ray attenuation capability, which reduces the dose and allows more flexibility in the clinical setting [31-35].

Hypoxia or oxygen deficiency is an essential feature of the microenvironment in solid tumors [36]. It is a significant regulative factor in tumor growth [37] and has long been known to have a crucial role in radiotherapy resistance [38-40]. Hypoxic tumors are often resistant to traditional cancer therapies, and there is a correlation between tumor hypoxia and advanced stages of malignancy. Previous studies have shown that hyperthermia treatment can also effectively resolve hypoxia. In addition to improving hypoxia, hyperthermia treatment can also effectively suppress DNA repair thereby greatly enhancing the efficacy of RT [41, 42]. Therefore, a strong synergistic effect could be efficiently generated by combining hyperthermia and nanomaterials-enhanced RT. In this study, we constructed  $Bi_2S_3$ nanorods as single-component omnipotent nanoagents and explored their competence as both radio sensitizers and photothermal adsorbing agents for combined PTT and RT. Our work not only introduces Bi-based nanostructures with highly integrated imaging and therapy abilities but also elucidates a detailed mechanism of their synergistic effect.

## Results

## Synthesis and characterization

Bi<sub>2</sub>S<sub>3</sub> nanorods were synthesized using the hydrothermal reaction according to the procedure described in previous studies [43-45]. The successful fabrication of Bi<sub>2</sub>S<sub>3</sub> nanorods was evidenced by high-resolution transmission electron microscope (TEM) imaging (Figure S1A&B) and energy dispersive spectroscopy (EDX) (Figure S2). The characterization of the nanoagents by TEM showed average diameters of 10-70 nm in length (Figure 1A). The UV-vis-NIR spectrum of the nanoagents exhibited a broad absorbance band from 700 nm to 1000 nm (Figure 1B) and the XRD pattern demonstrated that all the peaks were well indexed to the orthorhombic Bi<sub>2</sub>S<sub>3</sub> crystal (Figure 1C). When exposed to an 808 nm laser at a power density of 2 W/cm<sup>2</sup>, the nanoagents exhibited concentration- and time-dependent photothermal effects (Figure 1D). The dynamic light scattering (DLS) analysis showed that the hydrodynamic size of the nanorods was 155.4±2.8 nm (Figure S1C) and was almost unchanged in different media within 72 h (Figure S1D). No obvious change was detected for the DLS, absorbance, UV-vis-NIR and XRD characterizations of nanorods upon irradiation by NIR laser for different times (Figure S3A-C) demonstrating good thermal stability. Also, when the nanoagents were subjected to a temperature increase, no obvious change during four repeated laser on/off cycles was observed indicating stable photothermal conversion (Figure S3D).

# *In vitro* enhanced radiotherapy combined with photo-thermal treatment

The cell viability assays indicated that Bi<sub>2</sub>S<sub>3</sub> nanorods, even at concentrations up to 200 µg mL<sup>-1</sup>, caused no obvious cytotoxicity (Figure S4) confirming their good biocompatibility. No obvious influence on the cell viability was observed upon exposure to low-dose X-ray or lower-power NIR laser irradiation, whereas treatment with Bi<sub>2</sub>S<sub>3</sub> nanorods promoted the loss of cell viability. The combination of X-ray and NIR laser irradiation plus treatment with Bi<sub>2</sub>S<sub>3</sub> nanorods resulted in the most significant cell damage causing the death of a large number of cells (Figure 2A). The quantitative analysis of the cell viability confirmed that X-ray irradiation combined with photo-thermal treatment had the greatest cancer cell killing ability (Figure S5).

Next, a clonogenic survival assay, the gold standard technique for determining cellular radio sensitivity, was performed to evaluate the in vitro efficacy of RT. As expected, the high-Z Bi-based nanoagents exerted a radio-sensitization effect, and nanoagent-mediated hyperthermia synergistically enhanced the efficacy (Figure 2B). Using a linear-quadratic model, the sensitizing enhancement ratio of the nanoagent was calculated to be ~1.22, which upon NIR irradiation was ~1.34. To directly evaluate the DNA damage, a comet assay was conducted, which is a very sensitive method for detecting both single and double-strand DNA breaks in a single cell. As shown in Figure 2C, almost no comet could be observed in control cells. The tail could be observed at low-dose X-ray irradiation and

its length increased by  $1.5 \times$  due to the radio sensitizing effect of Bi. Importantly, upon both X-ray and NIR irradiation, cells treated with nanoagents gave rise to remarkably long stained tails, illustrating the most significant DNA damage (\*\*p< 0.01). The *in vitro* data presented above indicated that Bi<sub>2</sub>S<sub>3</sub> nanorods had a good radio-sensitizing effect and nanoagent-mediated hyperthermia synergistically strengthened the efficacy of RT.

### **Dual-modal imaging**

 $Bi_2S_3$  nanorods with high NIR absorbance are potentially ideal contrast agents for photoacoustic (PA) imaging, which is especially helpful in analyzing the information in the tumor area. We performed PA imaging to understand the distribution of the nanoagents inside tumors. Animal experiments were carried out under protocols approved by Soochow University Laboratory Animal Center. The nanoagents were intravenously (*i.v.*) injected into the tail vein of tumor-bearing mice, and then the cross-sectional PA signal of tumors was obtained. Before injection, the PA image showed observable but weak signals in the tumor region arising from the tumor blood, whereas PA signals remarkably increased after *i.v.* injection of the nanoagents indicating the gradual accumulation of  $Bi_2S_3$  in the tumor sites (Figure 3A). The dynamic MSOT images of tumors at different time points (0.5, 3, 6, and 24 h) showed that the PA signal reached a maximum value and lasted for as long as 24 h (Figure S6).

The X-ray attenuation property (HU value) of the nanoagents is shown in Figure S7 (iopromide was used as control). The slope of the HU value for the nanoagents was higher than that of a clinically used CT contrast agent (iopromide). The *in vivo* CT imaging indicated strong tumor contrast demonstrating the superior contrasting efficiency of the Bi<sub>2</sub>S<sub>3</sub> nanorods (Figure 3B). These imaging results collectively confirmed the interesting optical and X-ray absorbance properties of Bi<sub>2</sub>S<sub>3</sub> nanorods as an ideal contrast agent for CT and photoacoustic dual-modal imaging.



Figure 1. Characterization of Bi<sub>2</sub>S<sub>3</sub> nanorods. (A) TEM images (B) UV-vis-NIR absorbance spectra (C) XRD characterization of nanoagents (D) Photothermal curves of different concentrations of Bi<sub>2</sub>S<sub>3</sub> nanorods under 808 nm laser (2.0 W/cm<sup>2</sup>).



Figure 2. In vitro enhanced radiation therapy combined with photothermal treatment. (A) Representative fluorescence images of live (green) and dead (red) cells with various treatments. (B) Clonogenic survival assay of cells treated with X-ray alone, X-ray plus Bi<sub>2</sub>S<sub>3</sub> nanorods, and X-ray plus Bi<sub>2</sub>S<sub>3</sub> nanorods combined with NIR irradiation under a series of radiation doses of 0, 2, 4, 6, and 8 Gy. (C) Imaging of DNA fragmentation using comet assay in 4T1 cells with different treatments. Histograms correspond to quantification of tail DNA (%). The data are the means and standard deviation from three parallel experiments. More than 50 comets were analyzed in each experiment. *P* values were calculated by the student's test: \*\*p < 0.01.

## *In vivo* enhanced radiotherapy combined with photo-thermal treatment

We also tested the blood circulation behavior of  $Bi_2S_3$  nanorods in Balb/c mice bearing 4T1 tumors. According to the two-component pharmacokinetic model, the *pharmacokinetic* parameters were as follows:  $t1/2\alpha = 0.4$  h;  $t1/2\beta = 4.5$  h (Figure S8A). Meanwhile, the single-component pharmacokinetic model (C =  $C_0 e^{-Kt}$ ) was also used to calculate the blood half-life as follows: t1/2 = 4.69\*ln2 = 3.25 h. Furthermore, we evaluated the biodistribution of  $Bi_2S_3$  by determining the Bi content in the major organs and tumors. The results revealed that the %ID/g value of tumors was ~2.4% (Figure S8B).

After 15 min of NIR laser irradiation (0.75  $W/cm^2$ ), the temperature of tumors injected with  $Bi_2S_3$  increased to ~45 °C, whereas the tumors in the saline group were not heated (final temperature ~36 °C) (Figure 3C&D). The tumor growth curves from different groups (Figure 3E) showed that both low-dose X-ray irradiation and nanoagent-based hyperthermia exhibit limited inhibitory effects on the growth of 4T1 solid tumors. In the presence of nanoagents, X-ray irradiation increased tumor growth

inhibition attributable to the strong radio sensitizing effect of Bi. Most importantly, in the combination therapy group, remarkably suppressed tumor growth was observed, attributable to the synergistically enhanced therapeutic effect. It is possible that an increased dose of the nanomaterial and/or elevated dose of NIR power density/X-ray radiation dose is needed for complete eradication of tumors.

To compare the overall clinical efficacy as defined by morbidity-free survival, a Kaplan-Meier analysis was performed. Mice in each group were scored when the tumor volume increased five-fold. In this model, we found that the combined treatment was obviously superior to X-ray or NIR alone, further confirming the synergistic effect of nanoagent-mediated hyperthermia on the efficacy of RT treatment (Figure 3F). The anti-tumor efficacy of different treatments was further assessed using deoxynucleotidyl terminal transferase-mediated dUTP-biotin nick end labeling (TUNEL) of the tissues paraffin-embedded (Figure 3G). The combination treatment could induce tumor cell apoptosis to a relatively high level via downregulating the expression of anti-apoptosis protein Bcl-2 (Figure S9). The activated caspase-3 initiated a caspase-3-dependent mitochondrial pathway to induce apoptosis.

### Mechanism of synergistic effect

Based on the preceding experimental observations that Bi-based nanoagents could significantly enhance the therapeutic outcome of radiotherapy together with the photothermal effect, we performed isobologram analysis to determine the interaction between the photothermal therapy and radiotherapy of Bi<sub>2</sub>S<sub>3</sub> nanorods *in vitro* and *in vivo*. As shown in Figure S10, the inhibitory effect of PTT and RT on 4T1 cells was synergistic, as evidenced by the fact that data points in the isobologram are far below the line defining additive effects.



**Figure 3. Dual-modal imaging and enhanced radiation therapy combined with photothermal treatment** *in vivo*. (A) Photoacoustic images of tumor (B) CT images of tumor-bearing mice before and after *i.v.* injection of Bi<sub>2</sub>S<sub>3</sub> nanorods: liver (L), spleen (S), and tumor (T) (C) IR thermal images of tumor-bearing mice under 808 nm laser irradiation (0.75 W/cm<sup>2</sup>) (D) Temperature changes of tumors during laser irradiation (E) Tumor volume growth curves of mice after various treatments (F) Kaplan-Meier analysis (G) TUNEL analysis for apoptosis in tumor sections after different treatments.

Next, we investigated the possible mechanism of the synergistic effects. Hypoxia is one of the most important factors in the tumor micro-environment and is associated with tumor radio-resistance [46]. Previous studies have shown mild hyperthermia to be a radio-sensitizing agent because it could increase the blood flow into the tumor and thus improve the oxygen level in the tumor microenvironment. Thus, the effect of nanoagent-mediated hyperthermia on oxygen saturation within 4T1 tumors was assessed by measuring vascular saturated O<sub>2</sub> (sO<sub>2</sub>). Compared to controls, the injection of nanoagents upon NIR irradiation could not only increase the signal intensity of deoxygenated hemoglobin indicated by the blue color, but also markedly increased the signal intensity of oxygenated hemoglobin indicated by the red color (Figure 4A). By quantifying the average total  $sO_2$  in the tumor over time, we observed that sO<sub>2</sub> increased promptly by approximately 20% as compared with control (Figure 4B). Hypoxia is known to induce tumor radio resistance [47] through the activation of hypoxia-inducible factor-1 (HIF-1). The immunofluorescence assay for HIF revealed that controls nanoagent-mediated compared to hyperthermia significantly *inhibited* HIF-1a *expression*, confirming the decreased hypoxia and increased oxygenation (Figure 4C).

Cancer radiotherapy kills cancer cells mostly by inducing DNA damage, and thus if the damaged lesions are successfully repaired, the cancer cells would survive [48]. Of the known DNA repair-related proteins, Poly (ADP-ribose) polymerase (PARP) is involved in the single strand break repair of DNA [49, 50]. Also, as a major homologous recombination protein, Rad 51, dissociates from DNA double strand breaks in response to hyperthermia following exposure to ionizing radiation [51]. To verify the effects of mild photothermal heating on DNA repair, immunofluorescence staining for PARP and Rad 51 were performed. As shown in Figure 5A, nanoagent-mediated hyperthermia induced by NIR irradiation significantly decreased the activity of PARP and Rad 51. As compared with the saline control, the tumors treated with nanoagent-mediated hyperthermia showed a 73% and 46% decrease in the expression of PARP and Rad 51, respectively. Moreover, we determined the effect of X-ray on DNA repair and no obvious change was found (Figure S11). This implied that nanoagent-mediated hyperthermia could attenuate irradiation-induced DNA damage because hyperthermia can fix the DNA damage by interfering with the repair of radiation-induced DNA damage.



Figure 4. Effect of photo-thermal treatment on tumor oxygenation. (A) PA images of 4T1 tumors after different treatments by measuring signals at 750 nm and 850 nm representative of deoxygenated hemoglobin and oxygenated hemoglobin (B) Average total sO<sub>2</sub> of tumor measured over time (C) Representative images of immunofluorescent staining of HIF-1 from 4T1 tumors after treatment with saline/Bi2S<sub>3</sub>+NIR (positive expression: bright green regions). Histogram: quantification of HIF-1, determined from classified images (n = 3). Error bars represent the standard deviation of the mean. P values were calculated by the student's test: \*\*\*p < 0.001.



**Figure 5.** Effect of photo-thermal treatment on DNA repair. (A) Representative images of immunofluorescent staining of PARP (upper panels) and rad 51 (lower panels) in continuous sections from 4T1 tumors after treatment with saline/Bi<sub>2</sub>S<sub>3</sub>+NIR (positive expression: bright green regions. Scale bar corresponds to 100 µm. Histograms: quantification of PARP and rad 51 determined from classified images (n = 3). Error bars represent standard deviation of the mean. *P* values were calculated by the student's test: \*p < 0.05, \*\*\*p < 0.001. (B) Representative images of γH2AX immunofluorescent staining of 4T1 cells treated with saline/Bi<sub>2</sub>S<sub>3</sub>+NIR ( $\gamma$ -H2AX foci are shown as red fluorescence, cell nuclei stained with Hoechst shown as blue fluorescence). Histogram: quantitation of  $\gamma$ -H2AX immunofluorescent from classified images (n = 3). Error bars represent the standard deviation of the mean. P values were calculated by the student's test: \*p < 0.001.

Among various types of DNA damage, the most deleterious is the DNA double-strand break (DSB) [52, 53]. We labeled 4T1 cells with the immunofluorescent label phosphor-histone 2AX ( $\gamma$ H2AX), a marker of double-strand DNA breaks [54]. As shown in Figure 5B, negligible  $\gamma$ H2AX foci were observed in the cells treated with the nanoagents upon NIR irradiation implying limited DNA damage level induced by hyperthermia. However, a remarkably *increased* level

of  $\gamma$ *H2AX* occurred in cells treated with nanoagents upon both X-ray and NIR irradiation compared to those treated with X-ray irradiation alone (shown as red fluorescent spots). These results indicated that DNA repair is heat-sensitive and that nanoagent-mediated hyperthermia significantly increased levels of DNA strand breaks and promoted X-ray irradiation-induced DNA damage.

# Anti-invasion and anti-metastasis experiments in vitro and in vivo

Tumor metastasis is the leading cause of cancer mortality [55] and invasion and metastasis are among the greatest obstacles to successful tumor treatment [56, 57]. A significant finding of our study was that the treatment of nanoagent-mediated combination hyperthermia and X-ray/NIR irradiation not only inhibited tumor growth but also greatly suppressed tumor metastasis. To understand the underlying mechanism, transwell assays were performed and the results are presented in Figure 6A&S12. Compared to nanoagent-enhanced X-ray irradiation or nanoagent-based NIR irradiation, the combination treatment significantly reduced the number of migratory and invasive cells. Next, we examined the lungs and livers from mice using H&E staining. The results showed aggressive lung and liver metastases in the organs of control animals, whereas nanoagent-enhanced X-ray irradiation demonstrated superiority in treating metastasis over X-ray irradiation or NIR irradiation alone (Figure 6B&S13). Most significantly, no pulmonary metastasis was

observed in mice after combined treatments [58, 59]. Furthermore, far fewer blood vessels and lower expression of CD34, a commonly used marker for quantifying angiogenesis, were found in the combination treatment group (Figure S14, first row). The expression levels of the enzyme, MMP-2, and the angiogenic growth factor, VEGF, which are essential for angiogenesis and tumor development [60, 61], showed a similar trend (Figure S14).

# Biosafety and biocompatibility of Bi<sub>2</sub>S<sub>3</sub> nanorods

For the safety evaluation, the plasma levels of alanine transaminase (ALT), aspartate transaminase (AST), albumin (ALB), and alkaline phosphatase (ALP) for liver toxicity, and blood urea nitrogen (BUN) and creatinine for kidney toxicity were determined and are shown in Table S1. There was no significant difference in the data between Bi<sub>2</sub>S<sub>3</sub> nanorods- and saline-treated groups. Furthermore, the histological analysis of the liver, spleen, and kidney using the hematoxylin-eosin (HE) staining displayed no pathological changes compared to treatment with saline (Figure S15).



Figure 6. In vitro and in vivo effects of combination treatment on tumor metastasis. (A) Invasion and migration assay of 4T1 cells with different treatments. (B) Micrographs of H&E-stained lung and liver slices collected from different groups of mice. Tumor metastasis sites are highlighted by dashed circles and arrows. Scale bar corresponds to 100 µm.

### Discussion

As a common method for cancer therapeutics, the development and application of radio-therapy (RT) are limited by some bottlenecks. RT kills cancer cells mostly by inducing DNA damage, and thus if the damaged lesions are successfully repaired, the cancer cells would survive. Another limitation is of severe damage to surrounding normal tissues. **Bismuth-based** nanomaterials can improve the efficacy of RT for cancer cells because of several characteristic features such as the ability to enhance the radiation dose, application in multimodal imaging, ability to serve as CT contrast agents, and, above all, good biocompatibility. Exploiting these attractive attributes of bismuth, we have constructed a single-component powerful nanoagent, Bi<sub>2</sub>S<sub>3</sub> nanorods. The strong X-ray attenuation and high NIR absorption make Bi<sub>2</sub>S<sub>3</sub> nanorods attractive as contrast agents for PA and CT imaging, which favors precise positioning of the tumor. Importantly, we have shown that Bi<sub>2</sub>S<sub>3</sub> nanorod-mediated hyperthermia inhibited HIF-1 expression thereby causing decreased hypoxia and increased oxygenation. Cancer radiotherapy kills cancer cells mostly by inducing DNA damage, and thus if the damaged lesions are successfully repaired, the cancer cells would survive. In our study, nanorod-mediated hyperthermia induced by NIR radiation could significantly decrease the activity of DNA repair enzymes, PARP and Rad 51, and substantially interfere with DNA repair, potentiating DNA damage induced by ionizing radiation. Therefore, the integration of RT and nanomaterial-mediated hyperthermia generate а remarkable synergistic therapeutic effect by overcoming the inherent drawbacks of RT.

Tumor metastasis is the leading cause of cancer mortality and invasion and metastasis are among the greatest obstacles to successful tumor treatment. A significant finding of our study was that the combination treatment of nanoagent-mediated hyperthermia and X-ray irradiation not only inhibited tumor growth but also greatly suppressed tumor metastasis. Significantly, our results elucidated the underlying mechanism of inhibition of distant metastasis in our tumor model. We believe that this research provides important proof for nanomaterial-mediated hyperthermia synergistically enhancing the efficacy of RT.

## Materials and Methods

# Synthesis and characterization of Bi<sub>2</sub>S<sub>3</sub> nanoagents

The  $Bi_2S_3$  nanorods were fabricated by a facial

solve thermal method as previously described [42]. Tween-20 was employed to functionalize the nanorods, render them water-dispersible, and to improve their biocompatibility. The morphology of Bi<sub>2</sub>S<sub>3</sub> nanorods was observed by transmission electron microscopy (TEM, FEI TECNAI G2, 200 kV). Spectrophotometer (Shimadzu) was utilized to obtain the UV-vis-NIR absorbance spectra. The Rigaku D/max-2500 diffractometer ( $\lambda = 1.5418$  Å) was used to measure the powder XRD patterns of the dried Bi<sub>2</sub>S<sub>3</sub> nanorods products.

### Cell line and culture conditions

Murine breast carcinoma cell line (4T1) was purchased from Cell Bank of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in high-glucose Dulbecco's Modified Eagle Medium (DMEM, HyClone), supplemented with 10% fetal bovine serum (FBS, Gibco BRL), 1% penicillin/streptomycin (pen/strep, HyClone)) at  $37^{\circ}$ C with 5% CO<sub>2</sub> in a humidified incubator.

# Cytotoxicity evaluation and synergistic therapy *in vitro*

4T1 cells were seeded in 96-well plates at a density of 3×103 per well. After 24 h incubation, the cells had grown to 90% confluence and were distributed in five groups (saline, X-ray, Bi<sub>2</sub>S<sub>3</sub>+X-ray, Bi<sub>2</sub>S<sub>3</sub>+NIR, Bi<sub>2</sub>S<sub>3</sub>+X-ray+NIR). For radiotherapy alone, cells were irradiated with 4 Gy X-ray. For enhanced radiotherapy and hyperthermia, cells were treated with  $Bi_2S_3$  nanorods (100 µg/mL) for 24 h and then irradiated with X-ray or 808 nm NIR laser (2.0 W/cm<sup>2</sup>). For the combined group, cells were incubated with  $Bi_2S_3$  nanorods for 24 h and then subjected to co-exposure to NIR laser and X-ray irradiation. After treatment, 10 µL of CCK-8 was added, the cells were incubated for 2 h, and the absorbance at 450 nm was read using a microplate reader (BioTek, Synergy NEO).

### **Clonogenic survival assays**

4T1 cells were seeded in 6-well plates at different numbers (100, 200, 300, 600, 1000 cells) and allowed to adhere overnight. Subsequently, cells were treated with or without  $Bi_2S_3$  nanorods (100 µg/mL) for 24 h and then irradiated with or without X-ray under different doses of radiation (0, 2, 4, 6, and 8 Gy). Following irradiation, nanoagents were removed and fresh media was added. After 10 days of incubation, cells were washed with PBS before fixation with 100% methanol for 10 min. Methanol was aspirated and colonies were stained with Giemsa dye for 10 min. The number of colonies containing at least 50 cells was determined and the surviving fractions were calculated. The survival curves were plotted using a standard linear quadratic model and triplicate data of each sample were normalized. The sensitization enhancement ratio (SER) was calculated by the linear-quadratic model using origin software. According to the equation,  $y = \exp(-(a^*x+b^*x^2))$ , where y is the survival fraction, x is the dose of X-ray, 1/a is the mean lethal dose (D<sub>0</sub>), and SER = D<sub>0</sub>(with radiosensitizer) / D<sub>0</sub>(without radiosensitizer).

### **DNA** double-strand breaks

4T1 cells were seeded into 35 mm dishes at a density of  $2 \times 10^4$ . After 24 h incubation, the cells were fixed with 4% paraformaldehyde. Subsequently, 0.2% Triton X-100 was added to permeate the cells for 10 min. Fixed cells were rehydrated, centrifuged, and immunostained with anti- $\gamma$ -H2AX antibody (ab81299, Abcam) overnight at 4 °C. The cells were washed with PBS and incubated with the secondary antibody for 1 h at 37 °C. Finally, Hoechst (Invitrogen, CA) was added to stain the cell nuclei and the cells were visualized with a confocal laser microscopy (FV1200, OLYMPUS, Japan).

### Migration and invasion assays

For the migration assay, serum-free cell suspension was placed into the upper chamber of the 24-well transwell plate containing a polycarbonate membrane (8 µm pore size), and medium containing 10% FBS was placed in the lower chamber. For radiotherapy alone, cells were irradiated with 4 Gy X-ray. For enhanced radiotherapy or hyperthermia, cells were treated with  $Bi_2S_3$  nanorods (100 µg/mL) for 24 h and then irradiated with X-ray or 808 nm NIR laser (2.0 W/cm<sup>2</sup>). For combined group, cells were incubated with Bi2S3 nanorods for 24 h and then subjected to co-exposure to NIR laser and X-ray irradiation. After treatment, the cells on the upper chamber were scraped gently and washed with PBS. The cells migrated to the lower surface of the membrane were stained with Giemsa and counted in three independent high-power fields (200×). The invasion assay was performed using a polycarbonate membrane coated with Matrigel and the protocols were the same as for the migration assay.

### Tumor model

BALB/c mice were purchased from Chang Zhou Cavens *Laboratory* Animal Technology Co. Ltd. For the 4T1 tumor model, the right hind legs of BALB/c mice were subcutaneously implanted with 4T1 cells suspended in saline.

### CT and PA imaging in vivo

For PA imaging, 4T1 tumor-bearing mice were *i.v.* injected with 200  $\mu$ L of Bi<sub>2</sub>S<sub>3</sub> nanorods (10 mg/mL). Subsequently, the signal was recorded on

the photoacoustic instrument (MSOT in sight/Vision 256, iThera medical, Germany). Imaging parameters were as follows: the region of interest was 20 mm, and the wavelengths for each slice were from 700 nm to 900 nm. For CT imaging, tumor-bearing mice were injected *via* the tail vein with 200  $\mu$ L of Bi<sub>2</sub>S<sub>3</sub> nanorods (15 mg/mL) and a small X-ray CT (Gamma Medica-Ideas) was used to image. To obtain reconstruction images, the filtrated back projection method was performed to reconstruct images, which were analyzed by the Amira 4.1.2 system. The main parameters were as follows: tube voltage 80 kV, effective pixel size 50 µm, tube current 270 µA, field of view 1024 pixels × 1024 pixels.

### Synergistic therapy in vivo

When the tumor volume reached approximately 75 mm<sup>3</sup>, the animals were randomly divided into six groups (n = 8 per group) for various treatments: saline control, X-ray, X-ray + Bi<sub>2</sub>S<sub>3</sub>, Bi<sub>2</sub>S<sub>3</sub> +NIR, X-ray + Bi<sub>2</sub>S<sub>3</sub> + NIR. Mice bearing 4T1 tumors were *i.v.* injected with Bi<sub>2</sub>S<sub>3</sub> nanorods (2 mg/mL, 100 µL) and two hours later irradiated with 808 nm laser (0.75 W/cm<sup>2</sup>) for 15 min or 4 Gy X-ray (1.23 Gy/min). IR thermal camera (IRS E50 Pro thermal imaging camera) was used to record the temperature of the tumor surface and the tumor size was measured using a caliper every other day. Paraffin sections of tumor tissues were prepared for H&E and TUNEL staining.

Rabbit monoclonal HIF-1alpha antibody (dilution 1:100, Abcam,) and rabbit polyclonal anti-PARP, anti-Rad 51, anti-CD 34, anti-MMP-2, anti-VEGF (dilution 1:100, Abcam) were used for the staining of HIF-1alpha, PARP, Rad 51, CD 34, MMP-2, and VEGF, respectively. Briefly, tumor-bearing mice were treated *i.v.* with Bi<sub>2</sub>S<sub>3</sub> nanoagents or saline (control). After treatment, the dissected tumor tissues were incubated with various primary antibodies and then Alex 488-conjugated goat anti-rabbit secondary antibody (dilution 1:200, Abcam) following the vendor's instructions.

### **Tumor oxygenation measurements**

A photoacoustic imaging system (MSOT in sight/Vision 256, iThera Medical, Germany) was used to measure vascular oxygen saturation ( $sO_2$ ) over time before and after *i.v.* treatment with Bi2S3 nanorods. 750 nm and 850 nm *wavelength* illumination were selected for deoxygenated and oxygenated hemoglobin, respectively.

## Abbreviations

RT: radiotherapy; CT: computed tomography; PA: photpacoustic; HIF-1α: hypoxia-inducible factor; DNA: deoxyribonucleic acid; ROS: reactive oxygen species; PTT: photothermal therapy: TEM: transmission electron microscope; EDX: energy dispersive spectroscopy; XRD: X-ray diffraction; DLS: dynamic light scattering; NIR: near infrared spectra; multispectral optoacoustic tomography MOST: scanner; HU: hounsfield unit; sO<sub>2</sub>: saturated O<sub>2</sub>; (ADP-ribose) DSB: PARP: poly polymerase; double-strand break; yH2AX: phosphor-histone 2AX; H&E staining: hematoxylin-eosin staining; MMP-2: matrix metalloproteinase-2; VEGF: vascular endothelial growth factor; ALT: alanine transaminase; AST: aspartate transaminase; ALB: albumin; ALP: alkaline phosphatase; BUN: blood urea nitrogen; DMEM: dulbecco's modified eagle medium; FBS: fetal bovine serum; CCK-8: cell counting kit-8; SER: sensitization enhancement ratio.

### **Supplementary Material**

Blood chemistry analysis of mice, cell viability, X-ray CT images, H&E staining and immuno-histochemical analysis of tumors, the numbers of migratory and invasive cells, mechanism of combination cancer treatments on metastasis and H&E-staining of organs. Supplementary figures and tables. http://www.thno.org/v07p4087s1.pdf

### Acknowledgements

This work was partially supported by the National Basic Research Program of China (973 Program Grant No. 2014CB931900), National Natural Science Foundation of China (11575123 and 51402203), Natural Science Foundation of Jiangsu Province for Young Scholars (BK20140326), Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). C. G appreciates the support from the Open Project Program of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences (NSKF201611).

### **Competing Interests**

The authors have declared that no competing interest exists.

### References

- Harrington K, Billingham L, Brunner T, Burnet N, Chan C, Hoskin P, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011; 105: 628-39.
- (2) Falk S. Principles of cancer treatment by radiotherapy. Surgery (Oxford). 2006; 24: 62-5.
- (3) Tubiana M. Introduction to radiobiology. CRC Press. 2005.
- (4) Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett. 2012; 327: 48-60.
- (5) Noda A, Hirai Y, Hamasaki K, Mitani H, Nakamura N, Kodama Y. Unrepairable DNA double-strand breaks that are generated by ionising radiation determine the fate of normal human cells. J Cell Sci. 2012; 125: 5280-7.
- (6) Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014; 21: 251-9.

- (7) Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci. 2010; 107: 3522-7.
- (8) Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012; 18: 5585-94.
- (9) Lee CC, Reardon MA, Ball BZ, Chen CJ, Yen CP, Xu Z, et al. The predictive value of magnetic resonance imaging in evaluating intracranial arteriovenous malformation obliteration after stereotactic radiosurgery. J Neurosurg. 2015; 123: 136-44.
- (10) Liu J, Zhang J, Wang X, Li Y, Chen Y, Li K, et al. HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cance hela cells. Exp Cell Res. 2010; 316: 1985-93.
- (11) Song CW, Park H, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res. 2001; 155: 515-28.
- (12) Song C, Shakil A, Osborn J, Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia. 2009; 25: 91-5.
- (13) Iwata K, Shakil A, Hur W, Makepeace C, Griffin R, Song C. Tumour Po2 can be increased markedly by mild hyperthermia. Br J Cancer Suppl. 1996; 27: S217.
- (14) Fan W, Bu W, Shen B, He Q, Cui Z, Liu Y, et al. Intelligent MnO<sub>2</sub> nanosheets anchored with upconversion nanoprobes for concurrent pH-/H<sub>2</sub>O<sub>2</sub>-responsive UCL imaging and oxygen-elevated synergetic therapy. Adv Mater. 2015; 27: 4155-61.
- (15) Tian J, Chen J, Ge C, Liu X, He J, Ni P, et al. Synthesis of PEGylated ferrocene nanoconjugates as the radiosensitizer of cancer cells. Bioconjug Chem. 2016; 27 (6): 1518-24.
- (16) Chen Q, Feng L, Liu J. Zhu W, Dong Z, Wu Y, et al. Intelligent albumin-MnO<sub>2</sub> nanoparticles as pH-/H<sub>2</sub>O<sub>2</sub>-Responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy. Adv Mater. 2016; 27: 4155-61.
- (17) Dou Y, Guo Y, Li X, Wang S, Wang L, Lv G, et al. Size-Tuning Ionization To Optimize Gold Nanoparticles for Simultaneous Enhanced CT Imaging and Radiotherapy.
- ACS Nano 2016; 10: 2536-48.
  (18) Liu X, Zhang X, Zhu M, Lin G, Liu J, Zhou Z, et al. PEGylated Au@Pt Nanodendrites as Novel Theranostic Agents for CT Imaging and Photothermal/Radiation Synergistic Therapy. ACS Appl. Mater. Interfaces, 2017: 9: 279-85.
- (19) Yong Y, Cheng X, Bao T, Zu M, Yan L, Yin W, et al. Tungsten sulfide quantum dots as multifunctional nanotheranostics for in vivo dual-modal image-guided photothermal/radiotherapy synergistic therapy. ACS Nano. 2015; 9: 12451-63.
- (20) Xiao Q, Zheng X, Bu W, Ge W, Zhang S, Chen F, et al. A core/satellite multifunctional nanotheranostic for in vivo imaging and tumor eradication by radiation/photothermal synergistic therapy. J Am Chem Soc. 2013; 135: 13041-8.
- (21) Deng Y, Li E, Cheng X, Zhu J, Lu S, Ge C, et al. Facile preparation of hybrid core-shell nanorods for photothermal and radiation combined therapy. Nanoscale 2016; 8: 3895-9.
- (22) Wen L, Chen L, Zheng S, Zeng J, Duan G, Wang Y, et al. Ultrasmall biocompatible WO3-x nanodots for multi-modality imaging and combined therapy of cancers. Adv Mater. 2016; 28: 5072-9.
- (23) Al Zaki A, Joh D, Cheng Z, De Barros ALB, Kao G, Dorsey J, et al. Gold-loaded polymeric micelles for computed tomography-guided radiation therapy treatment and radiosensitization. ACS Nano. 2014; 8: 104-12.
- (24) Su XY, Liu PD, Wu H, Gu N. Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy. Cancer Biol Med. 2014; 11: 86-91.
- (25) Song G, Chen Y, Liang C, Yi X, Liu J, Sun X, et al. Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-z element and enzyme delivery for enhancing radiotherapy. Adv Mater. 2016; 28: 7143-8.
- (26) Rabin O, Perez JM, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater. 2006; 5: 118-22.
- (27) Liu J, Zheng X, Yan L, Zhou L, Tian G, Yin W, et al. Bismuth sulfide nanorods as a precision nanomedicine for in vivo multimodal imaging-guided photothermal therapy of tumor. ACS Nano. 2015; 9: 696-707.
- (28) Zinatloo-Ajabshir S, Salavati-Niasari M. Nanocrystalline Pr6O11: synthesis, characterization, optical and photocatalytic properties. New J Chem. 2015; 39: 3948-55.
- (29) Zinatloo-Ajabshir S, Salavati-Niasari M, Hamadanian M. Praseodymium oxide nanostructures: novel solvent-less preparation, characterization and investigation of their optical and photocatalytic properties. RSC Adv. 2015; 5: 33792-800.
- (30) Zinatloo-Ajabshir S, Salavati-Niasari M, Zinatloo-Ajabshir Z. Nd<sub>2</sub>Zr<sub>2</sub>O<sub>7</sub>-Nd<sub>2</sub>O<sub>3</sub> nanocomposites: new facile synthesis, characterization and investigation of photocatalytic behaviour. Mater Lett. 2016; 180: 27-30.
- (31) Ai K, Liu Y, Liu J, Yuan Q, He Y, Lu L. Large- scale synthesis of Bi<sub>2</sub>S<sub>3</sub> nanodots as a contrast agent for in vivo X-ray computed tomography imaging. Adv Mater. 2011; 23: 4886-91.
- (32) Kinsella JM, Jimenez RE, Karmali PP, Rush AM, Kotamraju VR, Gianneschi N, et al. X-Ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew Chem Int Ed. 2011; 50: 12308-11.
- (33) Salavati-Niasari M, Bazarganipour M, Davar F. Hydrothermal synthesis and characterization of bismuth selenide nanorods via a co-reduction route. Inorganica Chim Acta. 2011; 365: 61-4.

- (34) Zhu J, Wang J, Wang X, Wang X, Zhu J, Yang Y, et al. Facile synthesis of magnetic core-shell nanocomposites for MRI and CT bimodal imaging. J. Mater. Chem. B 2015; 34: 6905-10.
- (35) Salavati-Niasari M, Ghanbari D, Davar F. Synthesis of different morphologies of bismuth sulfide nanostructures via hydrothermal process in the presence of thioglycolic acid. J Alloys Compd. 2009; 488: 442-7.
- (36) Kim Y, Lin Q, Glazer PM, Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med. 2009; 9: 425-34.
- (37) Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47.
- (38) Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol. 2011; 100: 22-32.
- (39) Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol. 2007; 435: 295-321.
- (40) Sugrue T, Lowndes NF, Ceredig R. Hypoxia enhances the radioresistance of mouse mesenchymal stromal cells. Stem Cells. 2014; 32: 2188-200.
- (41) El-Awady R, Dikomey E, Dahm-Daphi J. Heat effects on DNA repair after ionising radiation: hyperthermia commonly increases the number of non-repaired double-strand breaks and structural rearrangements. Nucleic Acids Res. 2001; 29: 1960-6.
- (42) Oei AL, Vriend LE, Crezee J, Franken NA, Krawczyk PM. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015; 10: 165-178.
- (43) Zheng X, Shi J, Bu Y, Tian G, Zhang X, Yin W, et al. Silica-coated bismuth sulfide nanorods as multimodal contrast agents for a non-invasive visualization of the gastrointestinal tract. Nanoscale. 2015; 7: 12581-91.
- (44) Qazvini NT, Zinatloo S. Synthesis and characterization of gelatin nanoparticles using CDI/NHS as a non-toxic cross-linking system. J Mater Sci Mater Med. 2011; 22: 63-9.
- (45) Babu R, Thomas S, Hazzard MA, Friedman AH, Sampson JH, Adamson C, et al. Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions. J Neurosurg. 2014; 121: 262-76.
- (46) Griffin R J, Ogawa A, Williams BW, Song CW. Hyperthermic enhancement of tumor radiosensitization strategies. Immunol Invest. 2005; 34: 343-59.
- (47) Jain S, Coulter JA, Butterworth KT, Hounsell AR, McMahon SJ, Hyland WB, et al. Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiother Oncol. 2014; 110: 342-7.
- (48) Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014; 105: 370-88.
- (49) Robu M, Shah RG, Petitclerc N, Brind'Amour J, Kandan-Kulangara F, Shah GM. Role of poly (ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair. Proc Natl Acad Sci. 2013; 110: 1658-63.
- (50) Fisher AE, Hochegger H, Takeda S, Caldecott KW. Poly (ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly (ADP-ribose) glycohydrolase. Mol Cell Bio. 2007; 27: 5597-605.
- (51) Sak A, Stueben G, Groneberg M, Bocker W, Stuschke M. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell line. Br JCancer 2005; 92: 1089-97.
- (52) Zhou Y, Caron P, Legube G, Paull TT. Quantitation of DNA double-strand break resection intermediates in human cells. Nucleic Acids Res. 2013; 43: e19-e19.
- (53) Huhn D, Bolck HA, Sartori AA. Targeting DNA double-strand break signalling and repair: recent advances in cancer therapy. Swiss Med Wkly. 2013; 143: 523-9.
- (54) Kuo LJ, Yang LX. γ-H<sub>2</sub>AX-a novel biomarker for DNA double-strand breaks. In Vivo. 2008; 22: 305-9.
- (55) Martin TA, Ye L, Sanders AJ, Lane J, Jiang WG. Cancer invasion and metastasis: molecular and cellular perspective. 2000.
- (56) Van ZijlF, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. mutat. Mutat Res. 2011; 728: 23-34.
- (57) Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331: 1559-64.
- (58) Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A, Ribatti D, et al. Evaluation of microvascular density in tumors, Pro And Contra. Histol Histopathol. 2008; 23: 601-7.
- (59) Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996; 77: 362-72.
- (60) Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5: 1359-64.
- (61) Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005; 9: 267-85.